Johnson & Johnson experienced an 11% share price increase over the last quarter, coinciding with pivotal product-related milestones. The FDA's granting of Fast Track Designation for nipocalimab to treat Sjogren's disease marks a significant advancement, following its earlier Breakthrough Therapy Designation. This recognition could propel investor confidence, given the potential for accelerating therapeutic development addressing unmet needs. Additionally, Health Canada's approval for LAZCLUZE and the positive results from the ANTHEM-UC study contribute to the company's strengthened therapeutic portfolio. Despite broader market declines, with indices like the Dow Jones and Nasdaq experiencing downturns, Johnson & Johnson's recent regulatory wins and promising clinical data may anchor its investor appeal. The broader market trends include a minor 1.7% uptick over the past week and a 10% increase yearly, positioning JNJ's performance as a standout amid market challenges. This optimism reflects the company's resilience in achieving key development milestones, irrespective of broader economic uncertainties.

Assess the downside scenarios for Johnson & Johnson with our risk evaluation.

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Over the last five years, Johnson & Johnson's total shareholder return reached 68.59%. This period featured regulatory and legal challenges but also significant advancements in product approvals and strategic maneuvers. Noteworthy is the January 2022 FDA approval for XARELTO® to treat pediatric venous thromboembolism, bolstering the company's pharmaceutical segment. Another key development was J&J's announcement in November 2021 about its plan to separate the Consumer Health division, signaling a business focus shift.

The fiscal landscape was marked by a large one-off $7.8 billion loss impacting the financial results to December 2024, yet J&J continued its tradition of dividend increases, exemplified by the early 2025 rise to $1.24 per share. Meanwhile, despite J&J's underperformance compared to the broader US market's 10% climb in the past year, the company's initiatives in pharmaceuticals and legal resolutions anchored the longer-term investor confidence in the firm's potential amidst industry challenges.

Hold shares in Johnson & Johnson? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:JNJ.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com